Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

High-Risk Drug Imports To Be Delayed, FDA PREDICTs; Focus On Data Quality Can Avoid New 20 Percent Dragnet

Executive Summary

An FDA information technology system designed to identify high-risk imports for possible inspection should speed U.S. entry for about 80 percent of FDA-regulated products coming into the country

You may also be interested in...



FDA’s PREDICT Import Screening System Working As Predicted

An initial look at data from the first year of the import screening system’s full operation finds PREDICT is effective in directing FDA inspectors to high-risk products, Deputy Associate Commissioner for Regulatory Affairs Steve Solomon says.

FDA Counterfeit Screening Tool Gets Field Test In Ghana; Corning Prepares Device For Mass Production

FDA currently employs the CD3 in its laboratories and at a number of international mail facilities and other points of entry to the U.S. to screen cosmetics, foods, medical devices and cigarettes, as well as drugs.

PREDICT Gives FDA Head Start On Meeting House's Call For "Trade Facilitation"

FDA's PREDICT system should enable the agency to comply with the intent, if not the particulars, of a House Appropriations Committee suggestion to facilitate entry into the United States of goods that pose little risk.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS051588

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel